Ace inhibitor arb
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Comparative Analysis of ACE Inhibitors and ARBs
Introduction to ACE Inhibitors and ARBs
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are widely used medications for managing conditions such as hypertension, chronic kidney disease (CKD), and heart failure. Both drug classes target the renin-angiotensin system (RAS) but through different mechanisms. This article synthesizes recent research comparing the efficacy and safety of ACE inhibitors and ARBs.
Efficacy in Chronic Kidney Disease (CKD)
Kidney Failure and Cardiovascular Outcomes
Research indicates that both ACE inhibitors and ARBs significantly reduce the risk of kidney failure and major cardiovascular events in patients with CKD. A Bayesian network meta-analysis of 119 randomized controlled trials found that ACE inhibitors reduced the odds of kidney failure by 39%, while ARBs reduced it by 30% compared to placebo. Both drug classes also lowered the risk of major cardiovascular events, although ACE inhibitors showed a slight edge in reducing all-cause mortality.
Proteinuric Renal Disease
In patients with proteinuric renal disease, combination therapy with ACE inhibitors and ARBs has been shown to further decrease proteinuria compared to monotherapy. However, this combination therapy also resulted in a small but significant increase in serum potassium levels. The long-term benefits of this combination therapy on renal function preservation remain to be fully established.
Hypertension Management
Blood Pressure Control and Safety
A comprehensive review comparing ACE inhibitors and ARBs for hypertension management found no significant differences in their effectiveness for blood pressure control. However, ARBs were associated with fewer short-term adverse events, such as cough and angioedema, making them a preferable option for some patients .
Racial Differences in Efficacy
Studies have shown that black patients may have a reduced blood pressure response to ACE inhibitors or ARBs when used as monotherapy. However, this reduced efficacy is not observed when these medications are used in combination with other antihypertensive agents like calcium channel blockers or thiazide diuretics.
Diabetes Prevention
New-Onset Type 2 Diabetes
Both ACE inhibitors and ARBs have been associated with a reduced incidence of new-onset type 2 diabetes. A meta-analysis of 12 randomized controlled trials found that ACE inhibitors reduced the incidence by 27%, while ARBs reduced it by 23%. This suggests that these medications could be beneficial for patients with pre-diabetic conditions.
COVID-19 Considerations
Risk of Severe COVID-19
Concerns have been raised about the potential impact of ACE inhibitors and ARBs on COVID-19 severity due to their effect on ACE2 expression. However, multiple studies have found no significant increase in the risk of severe or lethal COVID-19 among users of these medications . In fact, some studies suggest that these drugs may be associated with a reduced risk of contracting COVID-19.
Conclusion
Both ACE inhibitors and ARBs are effective in managing conditions like CKD, hypertension, and in preventing new-onset type 2 diabetes. While ACE inhibitors may offer a slight advantage in reducing all-cause mortality in CKD patients, ARBs are generally better tolerated with fewer adverse effects. Current evidence also supports the continued use of these medications during the COVID-19 pandemic, as they do not increase the risk of severe disease. Further research is needed to explore the long-term benefits of combination therapy and the potential ethnic-specific effects of these drugs.
Sources and full results
Most relevant research papers on this topic